David Bejker, CEO

Wed, Aug 14, 2024 08:30 CET

Medium resolution

Original resolution

Subscribe

Related Releases

First gastroesophageal cancer patients enrolled in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025 Tue, Mar 26, 2024 09:14 CET